Healthcare


 Chemist Warehouse Merger with Sigma Healthcare to Reshape the ASX 200

Chemist Warehouse Merger with Sigma Healthcare to Reshape the ASX 200

January 16, 2025 03:20 PM AEDT| By Team Kalkine Media

Highlights,Sigma Healthcare (ASX:SIG) and Chemist Warehouse merger set to bring substantial index weight changes.,Analysts anticipate $537 million in trades from index trackers.,Passive fund flows likely to impact other ASX 200 members.,Sigma Healthc...

 Memphasys’ Antioxidant Profiling System Gains Recognition in Prestigious Publication

Memphasys’ Antioxidant Profiling System Gains Recognition in Prestigious Publication

January 16, 2025 11:20 AM AEDT| By Team Kalkine Media

Highlights:,Memphasys,Ltd (,ASX:MEM,) has received recognition for its proprietary,RoXsta,antioxidant profiling system through a key scientific publication.,The publication in the journal,Antioxidants,highlights,RoXsta's,ability to profile oxidative...

 Innovative Deals Drive Progress in HealthTech & Pharmaceuticals

Innovative Deals Drive Progress in HealthTech & Pharmaceuticals

January 16, 2025 11:00 AM AEDT| By Team Kalkine Media

Innovative Deals Drive Progress in HealthTech & Pharmaceuticals

 PYC Therapeutics (ASX:PYC) Investors Face AU$68 Million Loss

PYC Therapeutics (ASX:PYC) Investors Face AU$68 Million Loss

January 15, 2025 09:33 PM AEDT| By Team Kalkine Media

Highlights:,PYC Therapeutics (ASX:PYC) showcases diverse ownership with significant individual and insider stakes. -,Institutional investors hold a smaller fraction, suggesting growth potential. -,Private companies and the general public contribute t...

 Neuren Faces Market Challenges Amid European Progress

Neuren Faces Market Challenges Amid European Progress

January 15, 2025 11:46 AM AEDT| By Team Kalkine Media

Highlights,Neuren,Pharmaceuticals (NEU) sees stock decline despite EU progress.,Acadia Pharmaceuticals (ACAD) applies for Rett syndrome treatment approval in Europe.,Significant stock depreciation,noted,over the past year.,Shares of Neuren Pharmaceut...

 Biotechnology Partnership Seeks to Expand Rett Syndrome Drug into European Market

Biotechnology Partnership Seeks to Expand Rett Syndrome Drug into European Market

January 15, 2025 11:00 AM AEDT| By Team Kalkine Media

Biotechnology Partnership Seeks to Expand Rett Syndrome Drug into European Market

 Could Aroa Biosurgery Transform Soft Tissue Regeneration?

Could Aroa Biosurgery Transform Soft Tissue Regeneration?

January 15, 2025 11:00 AM AEDT| By Team Kalkine Media

Highlights,Dr. Adam Young's expertise enriches the advanced soft tissue regeneration technology at Aroa Biosurgery (ASX:ARX).,A distinct scientific methodology drives innovations in soft tissue repair.,The technology offers versatility across diverse...

 Will US Health Policy Changes Impact Australian Biotech Firms?

Will US Health Policy Changes Impact Australian Biotech Firms?

January 15, 2025 11:00 AM AEDT| By Team Kalkine Media

Highlights:,Robert F. Kennedy Jr. assumes the health secretary role amid policy uncertainties affecting Australian biotech firms in the US.,Companies such as CSL Limited (ASX:CSL), Cochlear Limited (ASX:COH), ResMed Inc. (ASX:RMD), and Fisher & Payke...

 Atomo Diagnostics Secures Long-Term Supply Agreement with Newfoundland Diagnostics

Atomo Diagnostics Secures Long-Term Supply Agreement with Newfoundland Diagnostics

January 14, 2025 12:28 PM AEDT| By Team Kalkine Media

Highlights,New Agreement,: Atomo Diagnostics enters a new five-year supply agreement with Newfoundland Diagnostics, worth approximately,AU$5.44 million,.,Exclusive Distribution Rights,: The agreement grants Newfoundland exclusive rights to distribute...

 Nanosonics (ASX: NAN) Appoints Gerard Dalbosco to the Board to Strengthen Global Strategy in Healthcare

Nanosonics (ASX: NAN) Appoints Gerard Dalbosco to the Board to Strengthen Global Strategy in Healthcare

January 14, 2025 12:26 PM AEDT| By Team Kalkine Media

Highlights,Gerard,Dalbosco,joins,Nanosonics,(NAN) board.,Dalbosco,brings significant,expertise,in finance, M&A, and strategy.,Nanosonics,continues to strengthen its healthcare sector position.,In an exciting development, Nanosonics (ASX:NAN), a leade...

 Telix Pharmaceuticals Shares Surge 7% After Outperforming FY24 Guidance

Telix Pharmaceuticals Shares Surge 7% After Outperforming FY24 Guidance

January 14, 2025 11:45 AM AEDT| By Team Kalkine Media

Highlights,Telix Pharmaceuticals shares rise 7% to AU$25.79 following a strong FY24 performance update.,Fourth-quarter unaudited revenue increased 46% year-on-year to US$142 million (AU$218 million), driving full-year revenue up 55% to US$517 million...

 Mesoblast Secures $260m to Power Cell Therapy Growth

Mesoblast Secures $260m to Power Cell Therapy Growth

January 14, 2025 11:38 AM AEDT| By Team Kalkine Media

Highlights,Mesoblast (MSB) completes a $260 million capital raise.,Funds to support,Ryoncil's,US launch and manufacturing expansion.,Shares dipped by 6.4% following the announcement.,Mesoblast Limited (ASX:MSB) has successfully raised $260 million th...

 Lumos partners with MedPro to broaden the US distribution of its FebriDx point-of-care respiratory test.

Lumos partners with MedPro to broaden the US distribution of its FebriDx point-of-care respiratory test.

January 14, 2025 11:00 AM AEDT| By Team Kalkine Media

Lumos partners with MedPro to broaden the US distribution of its FebriDx point-of-care respiratory test.

 Telix Pharmaceuticals Expands Portfolio with $372M ImaginAb Deal

Telix Pharmaceuticals Expands Portfolio with $372M ImaginAb Deal

January 13, 2025 01:20 PM AEDT| By Team Kalkine Media

Highlights,Major Acquisition:,Telix Pharmaceuticals is acquiring early-stage drug candidates and a proprietary biologics platform from ImaginAb, Inc. for an initial $73 million, with an additional $299 million tied to future milestones.,Next-Generati...

 4D Medical's Radioisotope-Free CT:VQ Technology Set for U.S. Department of Defense Pilot

4D Medical's Radioisotope-Free CT:VQ Technology Set for U.S. Department of Defense Pilot

January 13, 2025 01:16 PM AEDT| By Team Kalkine Media

Highlights:,U.S. DoD Pilot Program:,4D Medical has secured a pilot program with the U.S. Department of Defense to use its CT:VQ lung scanning technology, a major step toward formal FDA approval.,$1 Billion Market Opportunity:,The company aims to repl...

 Telix Pharmaceuticals (ASX:TLX) Expands Oncology Pipeline with $372M Asset Acquisition

Telix Pharmaceuticals (ASX:TLX) Expands Oncology Pipeline with $372M Asset Acquisition

January 13, 2025 11:13 AM AEDT| By Team Kalkine Media

Highlights:,Telix,Pharmaceuticals Ltd (,ASX:TLX,) secures next-generation cancer drug candidates through a $372 million acquisition agreement with,ImaginAb,, Inc.,The deal includes early-stage assets targeting high-grade neuroendocrine,tumors,, small...

 What Do Recent Insider Moves at SomnoMed Reveal?

What Do Recent Insider Moves at SomnoMed Reveal?

January 13, 2025 11:00 AM AEDT| By Team Kalkine Media

Highlights:,Chairman Gaetano Russo makes a significant stock purchase in SomnoMed.,Insiders collectively own around 7% of the company.,Insider activity over the last year has been focused on acquisitions, with no sales reported,Insider transactions c...

 AnteoTech's silicon-dominant anodes are creating a significant impact in the battery industry.

AnteoTech's silicon-dominant anodes are creating a significant impact in the battery industry.

January 12, 2025 11:00 AM AEDT| By Team Kalkine Media

Highlights:,AnteoTech advances lithium-ion batteries with silicon anodes, enhancing energy storage and reducing costs.,Collaborations with major companies demonstrate the commercial appeal of this innovative technology.,The focus remains on improving...

 Is the Biotech Sector on the Brink of a New Era of Growth?

Is the Biotech Sector on the Brink of a New Era of Growth?

January 11, 2025 11:00 AM AEDT| By Team Kalkine Media

Highlights:,A resurgence in global biotech M&A activity signals renewed interest and growth within the sector, with key acquisitions by companies such as Johnson & Johnson, Eli Lilly, and GlaxoSmithKline.,Dimerix (ASX:DXB) reports significant progres...

 Imugene (ASX:IMU) Receives $11.7M R&D Tax Refund to Boost Immunotherapy Developments

Imugene (ASX:IMU) Receives $11.7M R&D Tax Refund to Boost Immunotherapy Developments

January 10, 2025 02:52 PM AEDT| By Team Kalkine Media

Highlights,Imugene (IMU) receives $11.7M tax refund for R&D projects.,The refund is part of Australia's R&D tax incentive scheme.,The refund amount includes both principal and interest.,Imugene (ASX:IMU), an Australian-based immunotherapy company, ha...

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles






Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.